NCT01775098

Brief Summary

The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 21, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 24, 2013

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
Last Updated

May 11, 2017

Status Verified

May 1, 2017

First QC Date

January 21, 2013

Last Update Submit

May 10, 2017

Conditions

Gout

Keywords

Gouturic acidallopurinol

Outcome Measures

Primary Outcomes (1)

  • Duration of the gout crises

    Presence of inflammatory signs

    First 7 days after visit

Study Arms (2)

Allopurinol

EXPERIMENTAL

treatment with allopurinol

Drug: allopurinol

placebo

PLACEBO COMPARATOR

placebo comparator

Drug: allopurinol

Interventions

allopurinolDRUG

No arms will not be change as the study as been closed.

Allopurinolplacebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • More than 18 years old Able to sign informed consent Indication of long-term treatment with allopurinol Acute gout crisis

You may not qualify if:

  • Les than 18 years-old Unable to consent Contra-indication to allopurinol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Gout

Interventions

Allopurinol

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesCrystal ArthropathiesRheumatic DiseasesPurine-Pyrimidine Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

PurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

January 21, 2013

First Posted

January 24, 2013

Primary Completion

December 1, 2012

Study Completion

February 1, 2013

Last Updated

May 11, 2017

Record last verified: 2017-05